Sestamibi Imaging for the Characterization of Renal Masses

Sestamibi Imaging Study

Lay Title: Sestamibi Imaging for the Characterization of Renal Masses

Technical Title: 99mTc-sestamibi Imaging for the Characterization of Renal Masses:
Impact on Clinical Decision Making

Disease Type: Patients with recently diagnosed renal masses

Basic information:
The purpose of this study is to examine how doctors and patients use information from 99mTc-sestamibi SPECT/CT, a type of nuclear medicine scan, to decide how to manage newly diagnosed renal masses (kidney tumors). Patients on this study will undergo 99mTc-sestamibi SPECT/CT scans as part of their routine care.

Research Procedures (not a complete list):
Patients in this study will undergo 99mTc-sestamibi SPECT/CT scans as part of their routine care. Patients and physicians will be asked to complete questionnaires before and after the scan to determine whether results of the scan changed the patient and physician’s preferred treatment plan for the renal masses.

Eligibility Criteria (Not a complete list):
Inclusion Criteria:

• New diagnosis of a renal tumor (within the past 3 months).
• No evidence of metastatic disease (cancer that has spread beyond the kidney).
• Renal tumor is solid between 1.5 – 5.0 cm in size.

Exclusion Criteria:

• Presence of multiple solid renal tumors.
• Prior biopsy and diagnosis of the renal mass.
• Prior kidney cancer diagnosis.

For More Detailed Information, Contact:

• Brian Shuch, MD, Principal Investigator, Associate Professor of UCLA Urology
• Shirin Zavoshi, (310) 794-9493.